|
1.Volkers, A.C., E.R. Heerdink, and L. van Dijk, Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf, 2007. 16(9): p. 1054-62. 2.Tournier, M., et al., Patterns of antidepressant use in Quebec children and adolescents: trends and predictors. Psychiatry Res, 2010. 179(1): p. 57-63. 3.Zito, J.M., et al., Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf, 2006. 15(11): p. 793-8. 4.Schneeweiss, S., et al., Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics, 2010. 125(5): p. 876-88. 5.Devi, S., Antidepressant-suicide link in children questioned. Lancet, 2012. 379(9818): p. 791. 6.Kuo, C.C., et al., Prevalence, correlates, and disease patterns of antidepressant use in Taiwan. Compr Psychiatry, 2011. 52(6): p. 662-9. 7.Wu, C.S., et al., Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009. Pharmacoepidemiol Drug Saf, 2012. 8.DeBattista, C., Chapter 30. Antidepressant Agents, in Basic & Clinical Pharmacology, S.B.M. Bertram G. Katzung, Anthony J. Trevor Editor 2012. 9.Alan F. Schatzberg, C.B.N., The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed2009. 10.Alan F. Schatzberg, J.O.C., Charles DeBattista, Manual of clinical psychopharmacology. 6th ed2006. 11.Alan J. Gelenberg, M.P.F., John C. Markowitz, Jerrold F. Rosenbaum, Michael E. Thase, Madhukar H. Trivedi, Richard S. Van Rhoads. . Practice guideline for the treatment of patients with major depressive disorder. . Feb.16th 2012; Available from: http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. . 12.DeVane, C.L., Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol, 1999. 19(4): p. 443-66. 13.Leonard, H.L., et al., Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry, 1997. 36(6): p. 725-36. 14.Carrasco, J.L. and C. Sandner, Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract, 2005. 59(12): p. 1428-34. 15.Stahl, S.M., et al., SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr, 2005. 10(9): p. 732-47. 16.Domenic A. Ciraulo, R.I.S., and David J. Greenblatt, Clinical pharmacology and therapeutics of antidepressants. 2nd ed2011. 436. 17.Gerretsen, P. and B.G. Pollock, Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf, 2011. 10(5): p. 751-65. 18.Taurines, R., et al., Pharmacotherapy in depressed children and adolescents. World J Biol Psychiatry, 2011. 12 Suppl 1: p. 11-5. 19.Stahl, S.M. and A. Felker, Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr, 2008. 13(10): p. 855-70. 20.Croom, K.F., C.M. Perry, and G.L. Plosker, Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs, 2009. 23(5): p. 427-52. 21.Benjamin, S. and P.M. Doraiswamy, Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother, 2011. 12(10): p. 1623-32. 22.Stahl, S.M., Mechanism of action of trazodone: a multifunctional drug. CNS Spectr, 2009. 14(10): p. 536-46. 23.Rosenberg, D.R., Chapter 8. Tricyclic Antidepressants, in Pharmacotherapy for Child and Adolescent Psychiatric Disorders, P.A.D. Samuel Gershon , and David R. Rosenberg Editor 2002, Informa Healthcare. 24.Rosenberg, D.R., Chapter 9. Selective Serotonin-Reuptake Inhibitors, in Pharmacotherapy for Child and Adolescent Psychiatric Disorders, P.A.D. Samuel Gershon , and David R. Rosenberg, Editor 2002, Informa Healthcare. 25.Davanzo, P.A., Chapter 10. Novel (atypical) antidepressants, in Pharmacotherapy for Child and Adolescent Psychiatric Disorders, P.A.D. Samuel Gershon , and David R. Rosenberg Editor 2002, Informa Healthcare 26.Davanzo, P.A., Chapter 11. Monoamine Oxidase Inhibitors, in Pharmacotherapy for Child and Adolescent Psychiatric Disorders, P.A.D. Samuel Gershon , and David R. Rosenberg Editor 2002, Informa Healthcare. 27.Tsapakis, E.M., et al., Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry, 2008. 193(1): p. 10-7. 28.Uthman, O.A. and J. Abdulmalik, Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis. Curr Med Res Opin, 2010. 26(1): p. 53-9. 29.Geller, D.A., et al., Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry, 2001. 40(7): p. 773-9. 30.Wagner, K.D., et al., Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA, 2003. 290(8): p. 1033-41. 31.Sheehan, D.V. and K. Kamijima, An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. Int Clin Psychopharmacol, 2009. 24(2): p. 43-60. 32.Rynn, M.A., L. Siqueland, and K. Rickels, Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry, 2001. 158(12): p. 2008-14. 33.Emslie, G.J., et al., Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry, 2006. 45(6): p. 709-19. 34.Geller, D.A., et al., Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry, 2004. 43(11): p. 1387-96. 35.Wagner, K.D., et al., A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry, 2004. 61(11): p. 1153-62. 36.Carandang, C., et al., A review of escitalopram and citalopram in child and adolescent depression. J Can Acad Child Adolesc Psychiatry, 2011. 20(4): p. 315-24. 37.Emslie, G.J., et al., Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry, 2007. 46(4): p. 479-88. 38.March, J.S., et al., A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry, 2007. 62(10): p. 1149-54. 39.Olvera, R.L., et al., An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol, 1996. 6(4): p. 241-50. 40.Prakash, A., et al., An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol, 2012. 22(1): p. 48-55. 41.Mahmoudi-Gharaei, J., et al., Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study. Hum Psychopharmacol, 2011. 26(2): p. 155-60. 42.Meighen, K.G., Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J Child Adolesc Psychopharmacol, 2007. 17(1): p. 121-7. 43.U S Food and Drug Administration. 02/29/2012 [cited 2012 March 1st]; Available from: http://www.fda.gov/. 44.行政院衛生署. [cited 2012 March 1st]; Available from: http://www.doh.gov.tw. 45.eMC (eletronic Medicines Compendium). [cited 2012 23rd, May]; Available from: http://www.medicines.org.uk. 46.Desarkar, P., A. Das, and V.K. Sinha, Duloxetine for childhood depression with pain and dissociative symptoms. Eur Child Adolesc Psychiatry, 2006. 15(8): p. 496-9. 47.Ryan, N.D., Treatment of depression in children and adolescents. Lancet, 2005. 366(9489): p. 933-40. 48.Lim, C.J., et al., Antidepressant-induced manic conversion: a developmentally informed synthesis of the literature. Int Rev Neurobiol, 2005. 65: p. 25-52. 49.Chang, K., Challenges in the diagnosis and treatment of pediatric bipolar depression. Dialogues Clin Neurosci, 2009. 11(1): p. 73-80. 50.in Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care2005: Leicester (UK). 51.Hughes, C.W., et al., Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry, 2007. 46(6): p. 667-86. 52.Connolly, S.D. and G.A. Bernstein, Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry, 2007. 46(2): p. 267-83. 53.Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry, 2012. 51(1): p. 98-113. 54.Fritz, G., et al., Practice parameter for the assessment and treatment of children and adolescents with enuresis. J Am Acad Child Adolesc Psychiatry, 2004. 43(12): p. 1540-50. 55.Yang, S.S., et al., Treatment guideline of enuresis in Taiwan. Acta Paediatr Taiwan, 2001. 42(5): p. 271-7. 56.Zito, J.M., et al., Rising prevalence of antidepressants among US youths. Pediatrics, 2002. 109(5): p. 721-7. 57.Vitiello, B., S.H. Zuvekas, and G.S. Norquist, National estimates of antidepressant medication use among U.S. children, 1997-2002. J Am Acad Child Adolesc Psychiatry, 2006. 45(3): p. 271-9. 58.Percudani, M., et al., Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord, 2004. 83(2-3): p. 169-75. 59.行政院衛生署中央健康保險局業務執行報告-95年度. [cited 2012 15th, May]; Available from: http://www.nhi.gov.tw/Resource/webdata/Attach_8957_2_140業務執行報告.pdf. 60.行政院衛生署中央健康保險局業務執行報告-97年度. [cited 2012 15th, May]; Available from: http://www.nhi.gov.tw/Resource/webdata/Attach_10945_2_153執行報告.pdf. 61.行政院內政部統計年報-人口年齡分配. [cited 2012 14th, May]; Available from: http://sowf.moi.gov.tw/stat/year/y02-01.xls. 62.國家衛生研究院全民健康保險資料庫:各檔案間串檔變項說明. [cited 2012 Mar. 27th]; Available from: http://w3.nhri.org.tw/nhird/file_date/en_codedescribe.pdf. 63.Kao, Y.-H., et al., Classification of Pharmaceutical Products Reimbursed by National Health Insurance by the ATC System The Chinese Pharmaceutical Journal, 2002. 54: p. 283-290. 64.行政院衛生署中央健康保險局 2001 ICD-9-CM 疾病碼一覽表. 2012 [cited 2012 Mar. 27th]; Available from: http://www.nhi.gov.tw/Resource/webdata/Attach_3469_2_ICD2001-更新版.pdf. 65.行政院衛生署中央健保局-健保醫療服務-健保用藥. [cited 2012 26th, May]; Available from: http://www.nhi.gov.tw/query/query1.aspx?menu=18&menu_id=683&webdata_id=3468&WD_ID=756. 66.Drug Information Handbook. 20th ed: American Pharmacists Association (APhA). 67.Micromedex 2.0. [cited 2012 Feb 17th]; Available from: http://www.thomsonhc.com/micromedex2/librarian/ 68.FDA talk Paper. [cited 2012 15th, May]; Available from: http://www.fda.gov/cder/drug/advisory/mdd.htm. 69.Patel, V., Mental health in low- and middle-income countries. Br Med Bull, 2007. 81-82: p. 81-96. 70.Thapar, A., et al., Depression in adolescence. Lancet, 2012. 379(9820): p. 1056-67. 71.National Conference of State Legislatures-Children's Health Insurance Program Overview. [cited 2012 15th, May]; Available from: http://www.ncsl.org/issues-research/health/childrens-health-insurance-program-overview.aspx. 72.Sevilla-Dedieu, C., et al., Seeking help for mental health problems outside the conventional health care system: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD). Can J Psychiatry, 2010. 55(9): p. 586-97. 73.Vaswani, M., F.K. Linda, and S. Ramesh, Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry, 2003. 27(1): p. 85-102. 74.U S Food and Drug Administration. 02/29/2012 [cited 2012 16th, May]; Available from: http://www.fda.gov/. 75.Eaton, L., European agency approves use of fluoxetine for children and teens. BMJ, 2006. 332: p. 1407. 76.行政院衛生署. [cited 2012 16th, May]; Available from: http://www.doh.gov.tw. 77.Kurian, B.T., et al., Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med, 2007. 161(7): p. 690-6. 78.Marks, D.M., et al., Paroxetine: safety and tolerability issues. Expert Opin Drug Saf, 2008. 7(6): p. 783-94. 79.U.S FDA-Drug. [cited 2012 16th, May]; Available from: http://www.fda.gov/cder/drug/infopage/paxil/default.htm. 80.Pamer, C.A., et al., Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol Drug Saf, 2010. 19(2): p. 158-74. 81.Olfson, M., S.C. Marcus, and B.G. Druss, Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry, 2008. 65(1): p. 94-101. 82.Murray, M.L., C.S. de Vries, and I.C. Wong, A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child, 2004. 89(12): p. 1098-102. 83.Brown, M.L., A.W. Pope, and E.J. Brown, Treatment of primary nocturnal enuresis in children: a review. Child Care Health Dev, 2011. 37(2): p. 153-60. 84.Chang, P., et al., An epidemiological study of nocturnal enuresis in Taiwanese children. BJU Int, 2001. 87(7): p. 678-81. 85.Cher, T.W., G.J. Lin, and K.H. Hsu, Prevalence of nocturnal enuresis and associated familial factors in primary school children in taiwan. J Urol, 2002. 168(3): p. 1142-6. 86.Tai, H.L., et al., The epidemiology and factors associated with nocturnal enuresis and its severity in primary school children in Taiwan. Acta Paediatr, 2007. 96(2): p. 242-5. 87.Hetrick, S., et al., Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev, 2007(3): p. CD004851. 88.Ipser, J.C., et al., Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev, 2009(3): p. CD005170. 89.Couturier, J. and J. Lock, A review of medication use for children and adolescents with eating disorders. J Can Acad Child Adolesc Psychiatry, 2007. 16(4): p. 173-6. 90.Treasure, J., A.M. Claudino, and N. Zucker, Eating disorders. Lancet, 2010. 375(9714): p. 583-93. 91.Zink, M., S. Englisch, and A. Meyer-Lindenberg, Polypharmacy in schizophrenia. Curr Opin Psychiatry, 2010. 23(2): p. 103-11. 92.Barak, Y., M. Swartz, and Y. Baruch, Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: a retrospective analysis. Prog Neuropsychopharmacol Biol Psychiatry, 2011. 35(7): p. 1744-7. 93.Ricca V, M.E., Paionni A, Di Bernardo M, Cellini M, Cabras PL, Rotella CM., Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. Eat Weight Disord, 1999. 4(1): p. 10-4. 94.Chen, Y.C., et al., Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. J Headache Pain, 2012. 95.Lewis, D., et al., Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology, 2004. 63(12): p. 2215-24. 96.Malini Haria, A.F., Donna McTavish, Trazodone: A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs & Aging, 1994. 4(4): p. 331-55. 97.行政院衛生署中央健康保險局-藥材專區-藥品給付規定. [cited 2012 18th, May]; Available from: http://www.nhi.gov.tw/Resource/webdata/20928_1_藥品給付規定條文.doc. 98.Ma, J., K.V. Lee, and R.S. Stafford, Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health, 2005. 37(6): p. 434-42. 99.Rao, U. and L.A. Chen, Characteristics, correlates, and outcomes of childhood and adolescent depressive disorders. Dialogues Clin Neurosci, 2009. 11(1): p. 45-62. 100.Anderson, I.M., Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord, 2000. 58(1): p. 19-36. 101.Donoghue, J., Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl, 2000. 403: p. 57-61. 102.Rosholm, J.U., M. Andersen, and L.F. Gram, Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol, 2001. 56(12): p. 923-9. 103.Maric, N.P., et al., Factors influencing the choice of antidepressants: a study of antidepressant prescribing practice at University Psychiatric Clinic in Belgrade. Vojnosanit Pregl, 2012. 69(4): p. 308-13. 104.Hoffmann, F., et al., Outpatient treatment in German adolescents with depression: an analysis of nationwide health insurance data. Pharmacoepidemiol Drug Saf, 2012. 105.聯合新聞網-健康醫藥-醫藥新聞. 忘了他過敏 2醫師開錯藥起訴 [cited 2012 Jun 15th]; Available from: http://udn.com/NEWS/HEALTH/HEA1/7160951.shtml#ixzz1xsV54iY6. 106.財團法人醫院評鑑暨醫療品質策進會-資料下載-101年醫院評鑑與教學醫院評鑑說明會. [cited 2012 26th, May]; Available from: http://www.tjcha.org.tw/Upload/523DBEE4-F56F-4B20-941C-5D1D308BF069/8.醫院評鑑說明會簡報%20(第2.4-2.6章).pdf. 107.Hsieh, T.C., et al., Characteristics and consequences of drug allergy alert overrides in a computerized physician order entry system. J Am Med Inform Assoc, 2004. 11(6): p. 482-91. 108.Hunteman, L., et al., Analysis of allergy alerts within a computerized prescriber-order-entry system. Am J Health Syst Pharm, 2009. 66(4): p. 373-7. 109.許筱晴等人, 提升藥物過敏之標註性與正確性, in 台灣臨床藥學會2011. 110.MIMS.com-台灣. [cited 2012 20th,May]; Available from: http://www.mims.com/Taiwan. 111.WHOCC-ATC/DDD Index. [cited 2012 20th, May]; Available from: http://www.whocc.no/atc_ddd_index/. 112.Natsch, S., et al., Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis, 1998. 17(1): p. 20-4. 113.行政院衛生署-藥物、醫療器材、化妝品許可證查詢作業. [cited 2012 20th, May]; Available from: http://www.fda.gov.tw/licnquery/DO8180.asp.
|